Share Email Print
cover

Proceedings Paper

Development of antibody directed nanoparticles for cancer therapy
Author(s): R. Ivkov; S. J. DeNardo M.D.; L. A. Meirs; A. Natarajan; G. L. DeNardo M.D.; C. Gruettner; A. R. Foreman
Format Member Price Non-Member Price
PDF $17.00 $21.00

Paper Abstract

The pharmacokinetics, tumor uptake, and biologic effects of inductively heating 111In-chimeric L6 (ChL6) monoclonal antibody (mAb)-linked iron oxide nanoparticle (bioprobes) by externally applied alternating magnetic fields (AMF) were studied in athymic mice bearing human breast cancer HBT 3477 xenografts. In addition, response was correlated with calculated total deposited heat dose. Methods: Using 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide HCl, 111In-7,10-tetraazacyclododecane-N, N',N'',N'''-tetraacetic acid-ChL6 was conjugated to the carboxylated polyethylene glycol on dextran-coated iron oxide 20-nm particles, one to two mAbs per nanoparticle. After magnetic purification and sterile filtration, pharmacokinetics, histopathology, and AMF/bioprobe therapy were done using 111In-ChL6 bioprobe doses (20 mcg/2.2 mg ChL6/ bioprobe), i.v. with 50 mcg ChL6 in athymic mice bearing HBT 3477; a 153 kHz AMF was given 72 hours postinjection for therapy with amplitudes of 1,300, 1,000, or 700 Oe. Weights, blood counts, and tumor size were monitored and compared with control mice receiving nothing, or AMF, or bioprobes alone. Results: 111In-ChL6 bioprobe binding in vitro to HBT 3477 cells was 50% to 70% of that of 111In-ChL6. At 48 hours, tumor, lung, kidney, and marrow uptakes of the 111In-ChL6 bioprobes were not different from that observed in prior studies of 111In-ChL6. Significant therapeutic responses from AMF/bioprobe therapy were shown compared with no treatment. In addition, greatest therapeutic benefit was observed for the 700 Oe treatment cohort. Toxicity was only seen in the 1,300 Oe AMF cohort, with 4 of 12 immediate deaths associated with skin erythema and petechiae. Conclusion: This study shows that mAb-conjugated nanoparticles (bioprobes), when given i.v., escape into the extravascular space and bind to cancer cell membrane antigen.Thus, bioprobes can be used in concert with externally applied AMF to deliver thermoablative cancer therapy. Therapeutic benefit was observed with increasing calculated heat dose deposited in tumors.

Paper Details

Date Published: 22 February 2007
PDF: 8 pages
Proc. SPIE 6440, Thermal Treatment of Tissue: Energy Delivery and Assessment IV, 64400I (22 February 2007); doi: 10.1117/12.710712
Show Author Affiliations
R. Ivkov, Triton BioSystems, Inc. (United States)
S. J. DeNardo M.D., Univ. of California/Davis (United States)
L. A. Meirs, Univ. of California/Davis (United States)
A. Natarajan, Univ. of California/Davis (United States)
G. L. DeNardo M.D., Univ. of California/Davis (United States)
C. Gruettner, micromod Partikeltechnologie GmbH (Germany)
A. R. Foreman, Triton BioSystems, Inc. (United States)


Published in SPIE Proceedings Vol. 6440:
Thermal Treatment of Tissue: Energy Delivery and Assessment IV
Thomas P. Ryan, Editor(s)

© SPIE. Terms of Use
Back to Top